Last reviewed · How we verify
NCT07198815
A Preliminary Exploratory Clinical Trial to Evaluate the Efficacy of NPDR-01 Eye Drops in the Treatment of Non-Proliferative Diabetic Retinopathy
EARLY_PHASE1 trial testing Investigational Eye Drops (NPDR-01) in Non-proliferative Diabetic Retinopathy (NPDR) in 10 participants. Not yet recruiting.
1 December 2026
Quick facts
| Lead sponsor | Sichuan Academy of Medical Sciences |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 1 December 2025 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2026 |
Drugs / interventions tested
- Investigational Eye Drops (NPDR-01) — full drug profile →
Conditions studied
- Non-proliferative Diabetic Retinopathy (NPDR) — all drugs for Non-proliferative Diabetic Retinopathy (NPDR) →
- Diabetic Retinal Microangiopathy — all drugs for Diabetic Retinal Microangiopathy →
- Retinal Microaneurysms — all drugs for Retinal Microaneurysms →
- Diabetic Retinopathy — all drugs for Diabetic Retinopathy →
Sponsor
Sichuan Academy of Medical Sciences — full company profile →
Who can join
Adults 35 to 75, any sex, with Non-proliferative Diabetic Retinopathy (NPDR) or Diabetic Retinal Microangiopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to explore the preliminary clinical efficacy and safety of NPDR-01 eye drops in patients with non-proliferative diabetic retinopathy (NPDR).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07198815
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Sichuan Academy of Medical Sciences trials
Trials by the same sponsor.
- NCT07470775 — Early Dexmedetomidine and Sympathetic Regulation in Sepsis · Phase 4 · not yet recruiting
- NCT06501651 — Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy · Phase 4 · not yet recruiting
- NCT06398977 — Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients · NA · recruiting
- NCT06368713 — Exercise Improves Gastrointestinal Function in Peritoneal Dialysis Patients · NA · recruiting
- NCT05631847 — Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07198815 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sichuan Academy of Medical Sciences
- Last refreshed: 30 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07198815.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing